ABSTRACT A phase I study was conducted in 20 healthy subjects with 20 µg adeno-associated virus 2 (AAV2)-like particles displaying L2 residues 17–36 of both human papillomavirus (HPV) type 16 and HPV31 (AAVLP-HPV) or placebo. AAVLP-HPV vaccination was well tolerated and induced a modest L2-specific serum antibody titer...
Jade Alvarez, Pola Olczak, Hua-Ling Tsai et al.· Journal of Virology· 0 citations
Seeking a simple vaccine to protect against all cancer-associated human papillomaviruses (HPV), L2 residues 17-36 of both HPV16 and HPV31 displayed on the surface of an Adeno-Associated Virus-Like Particle (AAVLP-HPV) was developed. Here, a phase 1 randomized, placebo-controlled, double-blind clinical study has been co...
J. Prangsgaard, E. Huus, J. Alvarez et al.· medRxiv· 1 citation
Broad implementation of primary HPV-based screening, including self-sampling, will improve cervical cancer prevention and inform many more women of their high-risk HPV-positive status, and development of high-risk HPV-targeted therapeutics could further accelerate declines in cervical cancer by clearing prevalent infec...
L. Bruni, M. Brotons, Jade Alvarez et al.· Journal of the National Canc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.